Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business

/PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2023. First-quarter GAAP diluted EPS of $0.75 and...

Related Keywords

China ,Brazil ,Abbott Triclip ,Robertb Ford ,Drug Administration ,Core Laboratory ,European Union Medical Device Regulations ,Abbott Laboratories ,Linkedin ,Acelis Connected Health ,European Union Medical Device ,Facebook ,American College Of Cardiology Scientific Sessions ,Medical Devices ,Established Pharmaceuticals ,American College ,Cardiology Scientific Sessions ,Freestyle Libre ,Pediatric Nutrition ,Adult Nutrition ,Rapid Diagnostics ,Heart Failure ,Molecular Diagnostics ,Emerging Markets ,Southeast Asia ,Diabetes Care ,Structural Heart ,Aristocrats Index ,Investor Relations ,Private Securities Litigation Reform Act ,Caution Concerning Forward Looking ,Annual Report ,Consolidated Statement ,Quarter Ended March ,Operating Cost ,Specified Items ,Common Share ,Common Shares ,Diluted Earnings ,First Quarter Ended March ,Financial Information ,European Union ,Medical Device Regulations ,Vitro Diagnostics Medical Device Regulations ,Gross Margin ,Medical Device ,Vitro Diagnostics Medical Device ,Abbott ,